



# Balfour Capital Group Arvinas, Inc.

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies using its proprietary PROTAC® (PROteolysis TArgeting Chimeras) platform. This technology harnesses the body's natural protein disposal system to selectively degrade disease-causing proteins. Arvinas is advancing multiple investigational drugs through clinical development, including vepdegestrant, ARV-393, and ARV-102, targeting cancers and neurodegenerative diseases.

## 1. Top 5 Competitors

Arvinas operates in the biotechnology sector, focusing on protein degradation therapies. Its notable competitors include:

- Nurix Therapeutics (NRIX): Develops targeted protein modulation therapies.
- Kymera Therapeutics (KYMR): Specializes in targeted protein degradation.
- CytomX Therapeutics (CTMX): Focuses on conditional activation of biologics.
- Blueprint Medicines (BPMC): Develops targeted therapies for genomically defined cancers.
- Biohaven Ltd. (BHAVN): Works on treatments for neurological diseases.

## 2. Largest Institutional Shareholders

As of early 2025, significant institutional shareholders in Arvinas include:

- Vanguard Group Inc.: 10.27% ownership
- EcoR1 Capital, LLC: 9.78% ownership
- BlackRock, Inc.: 9.55% ownership

## 3. Management Team

Key members of Arvinas' management team are:

- John G. Houston, Ph.D.: Chairperson, CEO, and President
- Noah Berkowitz, M.D., Ph.D.: Chief Medical Officer
- Angela M. Cacace, Ph.D.: Chief Scientific Officer
- Andrew Saik: Chief Financial Officer and Treasurer



# Balfour Capital Group Arvinas, Inc.

## 4. Revenue

Arvinas reported revenues of \$426.9 million over the trailing twelve months as of Q1 2025, a significant increase from \$263.4 million in 2024. This growth is primarily attributed to collaboration revenues from partnerships with companies like Pfizer and Bayer.

## 5. Institutions with Buy Recommendations:

Several institutions have issued buy recommendations for Arvinas, including:

- Zacks Investment Research: Upgraded Arvinas to a "Buy" rating, citing positive earnings estimate revisions.

## 6. Analyst Sentiment Summary

Analyst sentiment towards Arvinas is moderately positive:

- Consensus Rating: Moderate Buy
- Analyst Breakdown: 12 Buy ratings, 8 Hold ratings, and 0 Sell ratings
- Average Price Target: \$19.42, representing a potential upside of approximately 198% from the current price

## 7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, Arvinas insiders have sold a total of 60,151 shares, amounting to approximately \$1.2 million. Notable transactions include:

- John G. Houston (CEO): Sold shares totaling \$768,443.16
- Ian Taylor: Sold shares totaling \$150,724.20
- Noah Berkowitz: Sold shares totaling \$74,372.22

There have been no reported insider purchases during this period.